Which thyroid-stimulating hormone level should be sought in hypothyroid patients under L-thyroxine replacement...

Area of Science:

• Endocrinology
• Cardiovascular Medicine
• Clinical Chemistry

Background:

• Thyroid hormone replacement therapy (LT4-RT) is standard for hypothyroidism.
• Cardiovascular risk factors like homocysteine and C-reactive protein (CRP) are potential concerns in treated hypothyroidism.
• The relationship between TSH suppression levels and these cardiovascular risk markers requires further investigation.

Purpose of the Study:

• To investigate the association between varying levels of thyroid-stimulating hormone (TSH) suppression and cardiovascular risk parameters in patients receiving L-thyroxine-replacement therapy (LT4-RT).
• To evaluate the impact of TSH levels on plasma homocysteine, CRP, fibrinogen, D-dimer, and serum cholesterol.

Main Methods:

• A cross-sectional study involving 402 hypothyroid patients on LT4-RT.
• Patients were categorized into three groups based on TSH levels (0.4-2, 2-5.5, and 5.5-20 mIU/l) with normal free T3 and T4.
• Comparisons were made with overt hypothyroid patients and healthy controls.

Main Results:

• Significantly different homocysteine and CRP levels were observed across the three TSH groups (p < 0.01).
• Homocysteine and CRP levels positively correlated with TSH and free T4 levels (p < 0.01).
• No significant differences in fibrinogen or D-dimer were found; lipid parameters showed a non-significant trend towards improvement.

Conclusions:

• A TSH target level below 2 mIU/l may be beneficial for reducing homocysteine and CRP levels in patients on LT4-RT.
• This TSH target may also offer potential benefits for lipid parameters.
• Further research could explore the clinical implications of optimizing TSH levels for cardiovascular health.